The compound could theoretically interact with medications affecting NAD+ metabolism, energy pathways, or the enzymes responsible for its clearance from the body
Precision becomes more critical here
Choosing Between 0.5 mL and 1 mL Syringes by Peptide | Peptide | Typical Dose | Reconstitution (per vial) | Concentration | Draw Volume | Recommended Syringe | |---|---|---|---|---|---| | BPC-157 | 250 to 500 mcg | 5 mg / 2 mL BAC | 2 to 500 mcg/mL | 10, 20 units | 0.5 mL or 1 mL, 31G | | TB-500 | 2,000, 2 to 500 mcg | 10 mg / 2 mL BAC | 5 to 000 mcg/mL | 40, 50 units | 1 mL, 29G | | GHK-Cu | 1,000, 2 to 000 mcg | 50 mg / 5 mL BAC | 10 to 000 mcg/mL | 10, 20 units | 0.5 mL or 1 mL, 31G | | Ipamorelin | 200 to 300 mcg | 5 mg / 2 mL BAC | 2 to 500 mcg/mL | 8, 12 units | 0.5 mL, 31G | | CJC-1295 (no DAC) | 100 to 200 mcg | 2 mg / 1 mL BAC | 2 to 000 mcg/mL | 5, 10 units | 0.5 mL, 31G | The 0.5 mL syringe improves accuracy for any draw below 20 units because each graduation mark represents 1 unit across a shorter, fatter barrel
There is no validated, publicly available reconstitution protocol for retatrutide, as it is an unlicensed investigational compound in the UK that may only be prepared by trained personnel within an approved clinical trial
10.1007/s00216-016-9313-6 46 EigenmannD
